Oncocyte to Report Second Quarter 2020 Financial Results on Wednesday, July 29

Rhea-AI Summary

Oncocyte Corporation (OCX) announced it will release its Q2 financial and operating results for the period ending June 30, 2020, on July 29, 2020, after U.S. market close. The company will host a conference call on the same day at 4:30 PM ET to discuss these results alongside recent developments. Oncocyte specializes in molecular diagnostics with products like DetermaRx™, aimed at assessing early-stage lung cancer patients for recurrence, and DetermaIO™, which identifies patients likely to respond to immunotherapies.

Positive

• Launch of DetermaRx™, a treatment stratification test for early-stage lung cancer patients.
• Development of DetermaIO™, a gene expression test for checkpoint immunotherapy response.

Negative

• None.

IRVINE, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, July 29, 2020, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13706018. To access the live webcast, go to the investor relations section on the Company’s website, or by clicking here:  http://public.viavid.com/index.php?id=140441.

About Oncocyte Corporation

Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

Source: Oncocyte Corporation

FAQ

When will Oncocyte Corporation release its Q2 2020 financial results?

Oncocyte Corporation will release its Q2 2020 financial results on July 29, 2020, after U.S. market close.

What is the purpose of the DetermaRx™ test launched by Oncocyte?

DetermaRx™ is designed to identify early-stage lung cancer patients at high risk for recurrence post-surgery.

What time is the conference call for Oncocyte's Q2 results?

The conference call for Oncocyte's Q2 results is scheduled for July 29, 2020, at 4:30 PM ET.

What does the DetermaIO™ test developed by Oncocyte do?

DetermaIO™ identifies patients who are more likely to respond to checkpoint immunotherapies.